Sign Up to like & get
recommendations!
1
Published in 2023 at "Current cancer drug targets"
DOI: 10.2174/1568009623666230418101511
Abstract: BACKGROUND Breast and ovarian tumors with pathogenic variants in BRCA1 or BRCA2 genes are more sensitive to poly (ADP-ribose) polymerase inhibitors (PARPi) treatment than wild-type tumors. Pathogenic variants in non-BRCA1/2 homologous recombination repair genes (HRR)…
read more here.
Keywords:
breast cancer;
t47d;
rad50;
rad50 deficient ... See more keywords